Accel-KKR Backs Checked In Care, Folds It Into Evaran Platform

Accel-KKR has acquired a majority stake in Checked In Care, a software platform serving non-medical home care agencies, and immediately folded it into Evaran, its existing portfolio company focused on clinical home care. The move signals the firm's bet that consolidating fragmented software tools across the $150 billion-plus home care industry can unlock meaningful margin expansion for providers juggling disconnected systems.

Deal terms weren't disclosed. But the transaction marks Accel-KKR's second major platform play in home care software within 18 months, following its investment in Evaran — itself a roll-up of clinical workflow tools for skilled nursing and therapy providers. The firm is now positioning the combined entity as a rare end-to-end solution spanning both clinical and non-clinical care coordination.

Checked In Care had carved out a niche among non-medical agencies — those providing companionship, meal prep, and daily living assistance rather than skilled nursing. Its software handles scheduling, caregiver matching, billing, and family communication. Evaran, by contrast, serves skilled home health agencies managing nurses, therapists, and clinical documentation requirements. The overlap was minimal. The strategic logic: most large home care organizations now operate both lines of business but run them on incompatible software stacks.

"We kept hearing the same thing from operators — they'd built one side of the business on our platform and the other side on someone else's, and nothing talked to each other," said Tom Benson, Evaran's CEO, in a statement. "This closes that gap."

The non-medical segment has historically been software's neglected stepchild in home care. Clinical platforms attracted venture dollars and PE interest because they sat closer to reimbursement dollars — Medicare, Medicaid, and insurance claims all flow through skilled care. Non-medical agencies, often paid privately or through long-term care insurance, were seen as lower-margin, harder-to-standardize businesses.

That calculus shifted as demographics caught up. The U.S. population over 65 is growing faster than the healthcare workforce, and non-medical care — cheaper, less regulated, more flexible — has become the release valve. Private-pay home care revenue grew 8% annually from 2018 to 2023, according to Home Care Pulse data, outpacing skilled care growth. Franchise models like Home Instead and Visiting Angels scaled nationally, creating a customer base large enough to support dedicated software.

Checked In Care entered that gap in 2018, built by former agency operators who understood the specific workflow pain points: last-minute caregiver call-outs, family demands for real-time visit updates, and the challenge of matching caregiver personality and skills to client needs. The platform emphasized caregiver experience — mobile-first, easy clock-in/out, two-way messaging with families — rather than the compliance-heavy feature sets that define clinical software.

By 2024, Checked In Care served over 300 agencies across 40 states, according to the company. Revenue details weren't disclosed, but the firm said average customer retention exceeded 95%, a rare figure in a market where software switching costs are relatively low and agencies often churn between point solutions.

Accel-KKR's investment memo here isn't subtle: buy fragmented software assets, integrate them, cross-sell the bundle to mid-market operators who can't afford enterprise contracts with Epic or Allscripts but need more than the patchwork of point solutions they're currently using.

The firm has deployed this playbook before — most notably in government contracting software (where it rolled up Unanet, Cobalt, and Sympaq) and transportation management systems (McLeod Software). The home care vertical offers similar conditions: thousands of independent operators, low software penetration, high tolerance for price increases if the product genuinely reduces administrative burden.

Evaran itself was assembled from prior acquisitions, though Accel-KKR hasn't publicized the specifics. The platform now includes clinical documentation, care plan management, scheduling, billing, and patient engagement tools. Adding Checked In Care gives it the non-medical layer — and, crucially, a unified data model that can track a patient's journey across both care types.

That data layer is the wedge. If Evaran can show agencies that a single patient record — one that follows someone from post-hospital skilled nursing through ongoing non-medical support — reduces duplicate data entry and lowers coordination errors, the 20-30% premium over point solutions starts to look defensible.

The timing benefits from several tailwinds. Staffing shortages have pushed agencies to expand service lines — a skilled nursing agency might add non-medical services to keep caregivers employed during census dips, or vice versa. But operating bifurcated software creates enough friction that many operators simply avoid the expansion.

Accel-KKR and Evaran are pitching the combined platform as a single source of truth for agencies running both clinical and non-medical lines. The value proposition: one patient intake, one family portal, one billing system, one caregiver app.

In practice, integration timelines for software roll-ups often stretch 18-24 months. Evaran's CTO acknowledged in the announcement that Checked In Care will continue operating as a standalone product through 2025 while engineering teams work on API connections and shared data models. Existing Checked In Care customers won't be forced onto the combined platform, though the company will "offer pathways" for migration.

That's standard post-acquisition language, but it highlights a tension in vertical software consolidation: customers chose point solutions precisely because they didn't want bloated, do-everything platforms. If Evaran bundles too aggressively or forces feature convergence, it risks alienating the very customers it just acquired.

The flip side: agencies operating dual service lines have been waiting for this. "We're running Evaran for our skilled side and Checked In Care for non-medical, and every week someone asks when they'll talk to each other," said Lisa Morgan, COO of a regional home care agency in Ohio, in a customer quote included in the announcement. Whether that sentiment is widespread or cherry-picked remains to be seen.

The economics depend on whether integrated workflows materially improve unit economics for agencies. If unified scheduling reduces caregiver idle time by even 5-10%, or if consolidated billing cuts administrative overhead, the software quickly pays for itself. If integration mostly creates a fancier dashboard without changing operational metrics, agencies will churn back to cheaper point solutions.

Evaran isn't the only firm chasing home care software consolidation. WellSky, backed by TPG Capital, has aggressively rolled up clinical and post-acute software over the past five years. Homecare Homebase, under Thoma Bravo ownership since 2016, recently added non-medical scheduling features. AlayaCare, a Canadian platform, raised $225 million in 2021 to expand across North America.

None of those platforms started in non-medical care, which gives Checked In Care a defensible wedge — if Evaran can retain its customer base and upsell them into clinical tools. But the inverse is also true: WellSky and Homecare Homebase have far larger installed bases on the clinical side and could easily build or acquire non-medical modules to compete.

Checked In Care's co-founders, who weren't named in the announcement, will stay on in unspecified leadership roles within Evaran. The deal structure — described as a majority investment, not an outright acquisition — suggests they retained some equity and decision-making authority, at least in the near term.

For the founding team, the upside is clear: access to Accel-KKR's capital, Evaran's enterprise sales team, and a faster path to scaling beyond the sub-$50M ARR threshold where most vertical software companies stall. The trade-off: product roadmap decisions now flow through a portfolio company structure optimizing for cross-sell rather than standalone product-market fit.

That shift shows up in the integration timeline. Checked In Care's 2025 product roadmap, previously focused on caregiver retention tools and family engagement features, will now prioritize interoperability with Evaran's clinical modules. Those might be the right features for dual-service agencies, but they're less relevant for the standalone non-medical shops that make up a chunk of Checked In Care's base.

The risk: losing product focus in pursuit of platform synergies that take years to materialize. The opportunity: becoming the default software stack for the growing cohort of agencies that refuse to pick between clinical and non-medical — they want both, and they want them to work together.

Accel-KKR's announcement didn't address workforce integration — how many Checked In Care employees will be absorbed into Evaran, whether duplicate roles will be consolidated, or how support and customer success teams will be structured. Historically, PE-backed software roll-ups trim overlapping functions within 6-12 months of closing.

For customers, the immediate question is pricing. Checked In Care operated on a per-caregiver, per-month model, typically ranging from $30-60 depending on feature tier and agency size. Evaran's pricing structure is more complex, involving base platform fees plus usage-based billing for claims volume. Whether the combined entity will offer bundled pricing or force agencies to navigate two separate contracts remains unclear.

Accel-KKR didn't disclose purchase price, revenue multiples, or whether the transaction involved debt financing. The firm typically targets software businesses generating $10M-$100M in revenue with EBITDA margins above 20%, suggesting Checked In Care likely falls in the $15M-$40M ARR range if the deal fits the firm's standard profile.

Checked In Care had raised minimal outside capital prior to the deal — a seed round in 2019 and a small growth equity injection in 2022, per PitchBook data. The company was profitable or near break-even, a rarity in venture-backed software but common among bootstrapped vertical SaaS companies built by former operators.

The combined Evaran-Checked In Care entity likely generates $60M-$120M in ARR, still well below the scale of WellSky or Homecare Homebase but large enough to compete for mid-market deals where those platforms are perceived as too expensive or complex.

Accel-KKR's fund strategy favors software consolidation in fragmented verticals, with target hold periods of 5-7 years. The firm will likely continue acquiring adjacent home care tools — patient engagement, caregiver training, revenue cycle management — to build Evaran into a platform large enough for a strategic exit to a healthcare IT incumbent or a public markets pathway.

Software roll-ups live or die on integration execution. If Evaran takes 18 months to ship meaningful interoperability between the two platforms, competitors will poach frustrated customers. If the combined product feels Frankensteined — bolted-together modules with inconsistent UX — agencies will stick with their current patchwork rather than pay a premium for a unified system that doesn't feel unified.

The optimistic case: Evaran moves fast, ships a genuinely integrated product by Q4 2025, and uses that as proof of concept to win enterprise deals from multi-state operators tired of managing six different software vendors. The company then becomes the acquirer of choice for smaller home care software tools, creating a flywheel where every new acquisition adds a feature set that makes the bundle stickier.

The pessimistic case: integration drags, Checked In Care customers churn to pure-play non-medical tools like ClearCare or AlayaCare's non-medical module, and Evaran ends up operating two separate products under one corporate umbrella — technically integrated but practically siloed. That outcome still works financially if both products grow independently, but it undercuts the strategic rationale for the deal.

Either way, the move sets a template. If Evaran succeeds, expect more PE firms to hunt for non-medical home care software assets to bolt onto clinical platforms. If it stumbles, the market will conclude that clinical and non-medical workflows are too different to unify profitably — and point solutions will continue to dominate.

The Accel-KKR thesis here extends beyond home care. It's a bet that vertical software consolidation — buying fragmented point solutions and integrating them into platforms — can still generate outsized returns even as software multiples compress and growth slows.

That playbook worked brilliantly from 2015-2021, when cheap debt and rising multiples let PE firms buy software assets at 4-6x revenue, bolt them together, and sell at 8-12x. But 2023-24 saw multiples collapse, debt costs spike, and buyers demand profitability over growth. Roll-ups that depend on multiple arbitrage — buying low, selling high based on scale alone — no longer pencil.

Which means consolidation strategies now have to create real operational value, not just financial engineering. If Evaran can show that integrated home care software genuinely improves agency margins — fewer billing errors, better caregiver utilization, lower admin overhead — then the premium pricing and customer retention follow. If integration just creates a bigger, clunkier product without measurable ROI, the deal becomes a cautionary tale.

The home care software market will serve as a live test case. If Accel-KKR's approach works here, the model replicates across every other fragmented vertical where operators juggle disconnected tools: field services, property management, government contracting, logistics. If it doesn't, PE firms will pivot back to buying standalone software businesses with clean financials and stop trying to force integration.